Pfizer's Ritlecitinib Meets Key Endpoint in Alopecia Areata
August 04 2021 - 7:54AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. on Wednesday said a Phase 2b/3 study of oral,
once-daily ritlecitinib met its main endpoint in patients with
alopecia areata, an autoimmune disease that causes hair loss on the
scalp and can also affect the face and body.
The New York drugmaker said ritlecitinib achieved the primary
efficacy endpoint of the proportion of patients with scalp hair
loss of 20% or less after six months of treatment versus
placebo.
Pfizer said the data, along with results from an ongoing
long-term study, will form the basis for planned future regulatory
filings, adding that there are currently no approved treatments in
the U.S. or Europe for alopecia areata.
Pfizer is also studying ritlecitinib for vitiligo, rheumatoid
arthritis, Crohn's disease and ulcerative colitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 04, 2021 07:39 ET (11:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024